Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

Abhishek D. Garg, Sanket More, Nicole Rufo, Odeta Mece, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    207 Citations (Scopus)

    Résumé

    The expression “immunogenic cell death” (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as “damage-associated molecular patterns”. Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.

    langue originaleAnglais
    Numéro d'articlee1386829
    journalOncoImmunology
    Volume6
    Numéro de publication12
    Les DOIs
    étatPublié - 2 déc. 2017

    Contient cette citation